Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

 
• By Alaric DeArment

The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.

Regeneron announced an analysis from the Phase I/II LINKER-MM1 trial of linvoseltamab • Source: Shutterstock

More from Immuno-oncology

More from Anticancer